| Literature DB >> 33976539 |
Shanze Li1, Yuming Wang1, Chunyan Li1, Na Yang1, Hongxin Yu1, Wenjie Zhou1, Siyu Chen1, Shenshen Yang1, Yubo Li1.
Abstract
BACKGROUND: Rhubarb, as a traditional Chinese medicine, is the preferred drug for the treatment of stagnation and constipation in clinical practice. It has been reported that rhubarb possesses hepatotoxicity, but its mechanism in vivo is still unclear.Entities:
Keywords: hepatotoxicity; metabolomics; network pharmacology; rhubarb
Mesh:
Substances:
Year: 2021 PMID: 33976539 PMCID: PMC8106470 DOI: 10.2147/DDDT.S301417
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Experimental Groups and Dosage of Each Group
| Groups | N | Dosage | Mode of Administration | Administration Time |
|---|---|---|---|---|
| Control group | 8 | 10 mL/kg/d | Continuous saline/Gavage | 20 days |
| Low-dose group | 8 | 1.5 g/kg/d | Continuous administration/Gavage | 20 days |
| Medium-dose group | 8 | 6 g/kg/d | Continuous administration/Gavage | 20 days |
| High-dose group | 8 | 12 g/kg/d | Continuous administration/Gavage | 20 days |
Figure 1Rhubarb total extract with negative ion mode BPI.
Identification Information for Rhubarb Total Extract Composition
| Ingredient Name | Molecular Formula | Rt. (Min) | m/z (Theoretical Value) | m/z (Actual Value) | Ppm | Fragmentation Information | |
|---|---|---|---|---|---|---|---|
| 1 | Epicatechin-(4β-8)-epicatechin-(4β-8)-catechin | C45H38O18 | 1.82 | 865.1980 | 865.1974 | −0.69 | 577.1228, 483.0695, 169.0170, 407.0745, 313.0255, 125.0257 |
| 2 | (+)-catechin | C15H14O6 | 3.02 | 289.0712 | 289.0698 | −4.84 | 245.0748, 579.0983, 203.0747, 151.0403, 136.0273 |
| 3 | Procyanidin B1 3-O-gallate | C37H30O16 | 17.17 | 729.1456 | 729.1481 | 3.43 | 651.1469, 577.1382, 407.0789, 364.0630, 289.0731, 163.0426 |
| 4 | Procyanidin 3,3′-di-O-gallate | C44H34O20 | 7.68 | 881.1565 | 881.1566 | 0.11 | 729.1423, 559.1328, 577.1371, 541.0665, 407.0714, 289.0776, 169.0195, 125.0238 |
| 5 | Sennoside A | C42H38O20 | 16.93 | 861.1878 | 861.1892 | 1.63 | 699.1359, 431.0953, 269.0416, 283.0689 |
| 6 | Chrysophanol | C15H10O4 | 31.89 | 253.0501 | 253.0502 | 0.40 | 225.0563, 209.0601, 197.0291 |
| 7 | Aloe-emodin | C15H10O5 | 28.90 | 269.0450 | 269.0452 | 0.74 | 240.0415, 211.0441, 183.0452 |
| 8 | Rhein | C15H8O6 | 29.64 | 283.0243 | 283.0258 | 5.30 | 239.0348, 211.0394, 183.0448 |
| 9 | Emodin | C15H10O5 | 30.91 | 269.0450 | 269.0452 | 0.74 | 241.0411, 225.0558, 197.0604, 183.0451 |
| 10 | Gallic acid | C7H6O5 | 1.04 | 169.0137 | 169.0143 | 3.55 | 125.0246 |
| 11 | Sennoside B | C42H38O20 | 12.48 | 861.1878 | 861.1873 | −0.58 | 699.1273, 386.1023 |
| 12 | Emodin-O-malonyl-glucoside | C24H22O13 | 26.71 | 517.0982 | 517.0979 | −0.58 | 473.1086, 253.0508 |
| 13 | Physcion-O-acetyl-glucoside | C24H24O11 | 9.41 | 487.1240 | 487.1239 | −0.21 | 283.0240, 240.0522 |
| 14 | Physcion | C16H12O5 | 29.10 | 283.0606 | 283.0614 | 2.83 | 269.0434, 240.0432, 225.0568 |
| 15 | P-Hydroxybenzoic acid-O-galloyl-glucoside | C20H20O12 | 2.32 | 451.0877 | 451.0873 | −0.89 | 451.0930, 289.0698, 281.0860, 151.0402, 143.0316 |
| 16 | Proanthocyanidin B1 | C30H26O12 | 1.49 | 577.1346 | 577.1353 | 1.21 | 483.0776, 289.0713, 407.0789, 169.0146 |
| 17 | Proanthocyanidin B2 | C30H26O12 | 1.74 | 577.1346 | 577.1339 | −1.21 | 577.1334, 559.1176, 493.0526, 451.0984, 425.0836, 407.0782, 289.0691, 245.0802, 125.0254 |
| 18 | Procyanidin B2 3ʹ-O-gallate | C37H30O16 | 3.22 | 729.1456 | 729.1443 | −1.78 | 577.1407, 289.0725, 169.0140, 125.0233 |
| 19 | Procyanidin B-5,3ʹ-O-gallate | C37H30O16 | 4.45 | 729.1456 | 729.1449 | −0.96 | 577.1301, 407.0771, 289.0724, 169.0121, 125.0264 |
| 20 | Aloe-emodin-8-O-β-D-glucopyranoside | C21H20O10 | 9.20 | 431.0978 | 431.0975 | −0.70 | 269.0456, 240.0417, 225.0561, 195.0813, 169.0121 |
| 21 | Emodin-1-O-β-D-glucoside | C21H20O10 | 18.14 | 431.0978 | 431.0977 | −0.23 | 269.0465, 240.0434, 169.0159, 125.0226 |
| 22 | Emodin-8-O-β-D-glucoside | C21H20O10 | 24.81 | 431.0978 | 431.0988 | 2.32 | 269.0451, 225.0549, 169.0119, 253.0509 |
| 23 | Rhein-8-O-β-D-glucopyranose | C21H18O11 | 9.95 | 445.0771 | 445.0773 | 0.45 | 283.0237, 239.0356, 211.0396, 891.1628 |
| 24 | Chrysophan-1-O-β-D-glucopyranose | C21H20O9 | 25.21 | 415.1029 | 415.1027 | −0.48 | 253.0507, 225.0549 |
| 25 | Gallic acid-3-O-(6ʹ-O-galloyl)-glucoside | C20H20O14 | 1.51 | 483.0775 | 483.0782 | 1.45 | 483.0780, 465.0664, 439.0826, 331.0663, 321.0301, 313.0497, 295.0297, 287.0656, 169.0137, 151.0013, 125.0237 |
| 26 | Catechin-7-glucoside | C21H24O11 | 1.44 | 451.1240 | 451.1245 | 1.11 | 451.1241, 289.0717, 245.0817, 227.0677, 203.0705, 161.0662 |
| 27 | Epicatechin-3-glucoside | C21H24O11 | 1.60 | 451.1240 | 451.1251 | 2.44 | 451.1229, 289.0698, 179.0323, 137.0249 |
| 28 | (-)-Epicatechin-3-O-Gallate | C22H18O10 | 8.26 | 441.0822 | 441.0836 | 3.17 | 441.0860, 331.0469, 289.0740, 245.0804, 205.0542, 203.0715, 193.0124, 179.0388, 169.0152, 125.0251 |
Figure 2Trend chart of body weight change of each group (A). Changes in the contents of ALT (B) and AST (C) in the serum samples of different groups. Liver pathological results (D) for the C group (a1-a2), L group (b1-b2), M group (c1-c2) and H group (d1-d2) with 200x magnification. n= 6, 7, 7, and 6, respectively.
Figure 3Plasma QC sample with positive ion mode BPI.
Figure 4Two-dimensional PCA graphs of four groups (A). PLS-DA graphs of normal control group and toxic group (B). PLS-DA graphs of normal control group and low-dose group (C). PLS-DA graphs of normal control group and low-dose group (D). PLS-DA graphs of normal control group and low-dose group (E).
Ionic Information for Potential Biomarkers for Liver Toxicity
| No. | Metabolites | Molecular Formula | Rt. (Min) | m/z (Measured Value) | m/z (Theoretical Value) | Error (ppm) | Adduct Form | Trend | VIP Value |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Dopamine | C8H11NO2 | 2.49 | 176.0704 | 176.0687 | 9.66 | M+Na | ↓* | 2.26 |
| 2 | Biopterin | C9H11N5O3 | 5.77 | 276.0524 | 276.0499 | 9.06 | M+K | ↓* | 1.89 |
| 3 | Choline | C5H14NO | 0.59 | 104.1077 | 104.1075 | 1.92 | M+H | ↓** | 2.37 |
| 4 | Dynorphin B (10–13) | C20H39N5O6 | 2.65 | 446.2906 | 446.2979 | −16.36 | M+H | ↑* | 1.94 |
| 5 | Coenzyme Q9 | C54H82O4 | 10.92 | 833.5842 | 833.5850 | −0.96 | M+K | ↓* | 1.97 |
| 6 | Cervonoyl ethanolamide | C24H36O3 | 2.88 | 373.2741 | 373.2743 | −0.54 | M+H | ↑* | 2.19 |
| 7 | P1,P4-Bis(5ʹ-uridyl) tetraphosphate | C18H26N4O23P4 | 10.93 | 812.9782 | 812.9836 | −6.64 | M+Na | ↓* | 1.91 |
| 8 | LysoPE(18:2) | C23H44NO7P | 4.91 | 478.2941 | 478.2934 | 1.46 | M+H | ↑** | 2.36 |
| 9 | 3-hydroxyphenyl 2-hydroxybenzoate | C13H10O4 | 3.13 | 253.0497 | 253.0477 | 7.90 | M+Na | ↑** | 3.02 |
Notes: *P value <0.05; and **P value <0.01. The upward arrow indicates that the level of metabolites in the toxic group is up-regulated compared to the control group. The downward arrow indicates that the level of metabolites in the toxicity group was lower than that in the control group.
Figure 5Heatmap of metabonomic data depicting the data structure of nine biomarkers.
Figure 6ROC curve for evaluating the predictive ability of nine rhubarb hepatotoxicity biomarkers.
Figure 7Rhubarb “ingredient-target” network diagram.
Figure 8“Metabolite-target” network diagram.
Figure 9Rhubarb potential hepatotoxicity target PPI network.
Figure 10GO gene enrichment function analysis diagram.
Figure 11KEGG pathway enrichment analysis diagram.